Geron Corporation

Stage 4 · Declining · week 4

As of Oct 22, 2026, Geron is in Stage 4, the downtrend phase, now in week 4 (since Sep 28, 2026). It closed at $1.13, 42.1% below its 52-week high and below its 200-day average, which is falling.

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. More about the company

$1.13

-3.41% today

$726M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is GERN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 13w

S2 23w

S3 14w

S4 27w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 5w → S4 13w → S1 12w → S4 1w → S1 2w → S2 23w → S3 14w → S4 27w → S1 4w → S4 10w → S1 3w → S4 9w → S1 5w → S2 13w → S3 6w → S4 7w → S1 3w → S2 4w → S1 1w → S4 4w current

Total tracked: 165 weeks across 20 stage runs.

GERN among Biotechnology217th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…217	GERNGeron Corporation	Stage 4 · wk 4	46	−8.9%

vs 52W High

-42.1%

$1.07 lo$1.95 hi

42.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 4

1w13w26w

Week 4, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-21.3%

200 DMA: $1.44 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.80x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-8.9%

-20.4%

-24.7%

YTD

-14.4%

-11.0%

Scan Membership

Breakout Watch

Latest: 2024-04-04

8 appearances in last 60 days. First seen: 2020-06-08.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 4 · Vol 0.80x

2026-10-21S4

Wk 4 · Vol 0.59x

2026-10-20S4

Wk 4 · Vol 0.39x

2026-10-19S4

Wk 4 · Vol 0.53x

2026-10-16S4

Wk 3 · Vol 0.42x

2026-10-15S4

Wk 3 · Vol 0.56x

2026-10-14S4

Wk 3 · Vol 0.53x

2026-10-13S4

Wk 3 · Vol 0.72x

2026-10-12S4

Wk 3 · Vol 0.37x

2026-10-09S4

Wk 2 · Vol 0.51x

2026-10-08S4

Wk 2 · Vol 0.92x

2026-10-07S4

Wk 2 · Vol 0.47x

Moving averages & range

50 DMA

$1.35

200 DMA

$1.44

52W High

$1.95

52W Low

$1.07

5D Low

$1.13

Resistance levels (recent highs)

20d High

$1.26

60d High

$1.63

120d High

$1.65

250d High

$1.95

Next resistance

+11.5%

to 20d High

ROE

-28.3%

Profit margin -33.1%

Dividend Yield

0.00%

P/B 3.3

Geron: quick answers

What stage is Geron in?

As of Oct 22, 2026, Geron (GERN) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 28, 2026 and is in week 4. What the four stages mean

Is Geron in an uptrend?

No. Geron is in a Stage 4 downtrend. It trades 21.3% below its 200-day average, which is falling.

How far is Geron from its 52-week high?

Geron closed at $1.13 on Oct 22, 2026, 42.1% below its 52-week high of $1.95. Its 52-week low is $1.07.

How has Geron performed over the past year?

As of Oct 22, 2026, Geron is down 11.0% over the past year and down 14.4% so far in 2026.

Which sector and industry is Geron in?

Geron is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.